The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 10th Edition

NOW IN TEN EDITIONS!

While tests run on lab-based analyzers in hospitals and reference labs remain the bedrock of IVD revenues, point of care has always been seen as the growth area.  For as long as Kalorama Information has covered point of care diagnostics, and this now spans 2 decades, point of care tests are the opportunity area.  Point of care as implied in the name is defined as tests that can be meaningful in a provider visit, or in the patients home.  

How can diagnostics promote wellness? How can diagnostics improve patient-provider encounters?  How can tests promote better selection and stewardship of drugs?  How can tests facilitate patient home or nursing home of the future? How can diagnostics ensure the next pandemic, if and when it arrives is appropriately handled?  The answers to these questions in many ways rely on the success of point-of-care solutions.

And because of this contribution, Point of Care diagnostics can earn a higher pricing and larger revenue growth than economized lab-based tests.  The tests covered in this report tend to grow at higher rates than overall IVD market.  

Enhanced Segmentation - Many Reports in One

Here are just some of the areas covered in this report

• Glucose
• Coagulation
• CRP
• Other Cardiac Markers
• Coagulation
• Colon Cancer
• Pregnancy / Fertility
• Drugs of Abuse
• hbA1c
• Cholesterol
• HIV
• COVID-19
• Other Infectious Disease
• Critical Care Tests

These are detailed with market sizing and forecast in this report.

As discussed in this report, The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 9th Edition, POC testing has skyrocketed in the last 20 years as demand for accurate and rapid testing has blossomed both inside and outside the hospital setting. An in-depth look at the global POC testing market yielded several interesting facts that are explored in this study. Emerging technological innovations in smartphones, biosensors, lab-on-a-chip and wearable devices are influencing the POC landscape. The driving force behind these innovations in the health arena is to provide expedited diagnosis where the patient is seen or in the patient’s home.  

Venue Market Analysis

POC tests are performed in a wide range of geographical locations such as:

• Hospital departments such as emergency departments, operating rooms, intensive care units, and others
• Physicians’ offices
• Hospital clinics
• Retail clinics
• Pharmacies
• Homes – With testing performed by patients, visiting nurses, or other caregivers
• Nursing homes

POC testing may be performed by laboratory personnel, but often it is performed by non-laboratory personnel such as physicians, nurses, assistants in medical offices, emergency medical technicians (EMTs), medics, pharmacists, and the patients themselves (self-testing). Some POC tests are manual tests, often performed with technologies based on dipsticks or strips, lateral flow cassettes, or other manual tests. There are also many small, portable instruments that have been developed for use in POC settings. With the advances in miniaturization and microfluidics that have occurred in recent years, a growing number of small, handheld devices are reaching the POC market for a range of different testing applications.

Regional Coverage

POC is an international market and Kalorama reflects this with regional coverage.  

Analysis is anchored by:

• Europe
• Japan
• United States
• Rest of World

However other countries and regions discussed in the report include:

• Australia
• Canada
• China
• France
• Germany
• India
• Italy
• South Korea
• Spain
• Sweden
• Switzerland
• Latin America
• Middle East

Corporate Profiles

Moreover, POC test devices have contributed significantly to the growth of the overall diagnostics market over the past 10 years. More diagnostic manufacturers have pursued CLIA waiver status for their POC devices and CE Mark for POC or self-use.  At the same time, more decentralized test venues invest in non-waived rapid tests and instruments.  POC testing appears to be headed for an even bigger role in diagnosis and monitoring patient care.  New technologies are allowing POC devices to produce quantitative lab-quality test results that can be transferred automatically to an information system, a remote caregiver service for consultation or an electronic medical record. Rapid tests are beginning to fold into the point of care arena because they allow the physician to treat the patient before they leave the clinic or office.

This report breaks out point of care testing by segment.

Among the top and/or innovative competitors discussed within Corporate Profiles are:

• 1 Step Dectect Associates, LLC
• Abbott Laboratories
• Abingdon Health Ltd.
• Accessbio, Inc.
• Accubiotech Co, Ltd.
• Acon Laboratories, Inc
• Aerscher Diagnostics, Llc
• Alfa Scientific Designs, Inc
• American Bio Medica Corporation
• Arkray, Inc.
• Artron Laboratories, Inc
• Ascensia Diabetes Care Holdings Ag
• Atlas Link Biotech Co., Ltd
• Autobio Diagnostics Co., Ltd
• Beckman Coulter, Inc
• Becton Dickinson (Bd)
• Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
• Bhat Bio-Tech India Private Ltd. (Bbi)
• Binx Health
• Biolytical Laboratories
• Biomedomics, Inc
• Biomeme, Inc
• Biomerica, Inc.
• Biomerieux Sa
• Bio-Rad Laboratories Inc.
• Biosensia Ltd.
• Biotron Diagnostics, Inc.
• Boditech Med Inc
• Boson Biotech Co. Ltd
• Btnx Inc.
• Calypte Biomedical Corporation
• Cepheid, Inc
• Chembio Diagnostics, Inc.
• Church & Dwight Co. Inc
• Clarity Diagnostics, Llc
• Confirm Biosciences
• Ctk Biotech, Inc.
• Cue Health
• Danaher Corporation
• Dexcom, Inc
• Dialab Gmbh
• Diasys Diagnostic Systems Gmbh
• Diazyme Laboratories, Inc.
• Dna Electronics Ltd. (Dnae)
• Dr. Fooke-Achterrath Laboratorien Gmbh
• Dxgen Corp.
• Eiken Chemical Co Ltd.
• Ekf Diagnostics Holdings Plc
• Elitechgroup S.A.S.
• Enterix, Inc. (Clinical Genomics)
• Eurobio Scientific
• Everlywell
• Exact Sciences
• Ey Laboratories
• First Check Diagnostics Llc
• Genbio
• Genedrive Plc
• Getein Biotech Inc.
• Glysby Diagnostics
• Helena Laboratories
• Hemosure, Inc.
• Horiba, Ltd.
• Immune Iq
• Immunosciences Lab, Inc.
• Immunostics, Inc
• Jal Innovation Pte Ltd
• Jant Pharmacal Corporation
• J. Mitra & Co Pvt. Ltd
• Lamdagen Corporation
• Lifescan, Inc
• Lifesign, Llc
• Lightdeck Diagnostics
• Lumiradx Uk Limited
• Macherey-Nagel Gmbh & Co. Kg
• Medix Biochemica
• Medmira, Inc
• Medtronic, Inc.
• Menarini Diagnostics Srl.
• Meridian Bioscience, Inc
• Mico Biomed Usa
• Nano-Ditech Corporation
• Ng Biotech
• Noble Medical, Inc
• Nova Biomedical Corp.
• Oasis Diagnostics Corporation
• Operon S.A.
• Opko Health, Inc
• Orasure Technologies, Inc.
• Polymedco, Inc
• Polymer Technologies, Inc (Pts Diagnostics)
• Preventis Gmbh
• Princeton Biomeditech Corporation
• Quantumdx Group Limited
• Quidelortho Corporation
• Radiometer Medical A/S
• Randox Laboratories Limited
• Response Biomedical Corp
• Reszon Diagnostics International Sdn. Bhd.
• Rheonix, Inc
• Roche Diagnostic Corporation
• Savyon Diagnostics
• Sekisui Diagnostics Llc
• Siemens Healthineers Gmbh
• Sysmex Corporation
• Techlab, Inc.
• Trinity Biotech Plc
• Trividia Health
• Tulip Diagnostics Ltd (Tulip Group)
• Vedalab
• Veredus Laboratories Pte Ltd
• Werfen

Scope and Methodology

The  geographic scope of The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 10th Edition is global, with information for specific geographical regions, world demographics, and other general issues affecting the market. The market summary includes total market values, market analysis by product, test usage, technology, region, end-use and a competitive analysis of leading providers.  Additionally, key company profiles are included.

All market data pertains to the world market at the manufacturers’ level. The market includes manufacturer tests excluding services.  The base year for data was 2022, including updates and reexaminations stemming from the impact of the COVID-19 pandemic. Forecast data is provided for 2022 through 2026. Compound annual growth rates (CAGRs) are provided for 2022-2026 periods for each segment covered.  Competitive analysis is provided for the year 2022 along with regional breakdowns.  The forecasted market analysis for 2022-2026 was largely based on demographic trends, new developments, innovative technology and global expansion.